Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Ritholtz Wealth Management

Ritholtz Wealth Management trimmed its holdings in Becton, Dickinson and Company (NYSE:BDXFree Report) by 13.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,631 shares of the medical instruments supplier’s stock after selling 246 shares during the period. Ritholtz Wealth Management’s holdings in Becton, Dickinson and Company were worth $398,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in BDX. Fairfield Bush & CO. acquired a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at approximately $114,000. Sequoia Financial Advisors LLC increased its holdings in shares of Becton, Dickinson and Company by 11.3% in the 1st quarter. Sequoia Financial Advisors LLC now owns 2,923 shares of the medical instruments supplier’s stock valued at $778,000 after acquiring an additional 297 shares during the last quarter. Brighton Jones LLC increased its holdings in shares of Becton, Dickinson and Company by 8.8% in the 1st quarter. Brighton Jones LLC now owns 1,383 shares of the medical instruments supplier’s stock valued at $368,000 after acquiring an additional 112 shares during the last quarter. Zions Bancorporation N.A. increased its holdings in shares of Becton, Dickinson and Company by 13.0% in the 1st quarter. Zions Bancorporation N.A. now owns 504 shares of the medical instruments supplier’s stock valued at $134,000 after acquiring an additional 58 shares during the last quarter. Finally, Mather Group LLC. increased its holdings in shares of Becton, Dickinson and Company by 26.0% in the 1st quarter. Mather Group LLC. now owns 1,346 shares of the medical instruments supplier’s stock valued at $358,000 after acquiring an additional 278 shares during the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Becton, Dickinson and Company

In other news, SVP Thomas J. Spoerel sold 282 shares of the stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total value of $67,197.78. Following the completion of the transaction, the senior vice president now owns 2,276 shares of the company’s stock, valued at $542,348.04. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.31% of the company’s stock.

Wall Street Analysts Forecast Growth

BDX has been the subject of a number of research analyst reports. Morgan Stanley lowered their price target on Becton, Dickinson and Company from $310.00 to $280.00 and set an “overweight” rating for the company in a report on Monday, December 4th. Raymond James boosted their price target on Becton, Dickinson and Company from $269.00 to $275.00 and gave the company an “outperform” rating in a report on Wednesday, January 3rd. Finally, Barclays boosted their price target on Becton, Dickinson and Company from $301.00 to $305.00 and gave the company an “overweight” rating in a report on Monday, February 5th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, Becton, Dickinson and Company currently has an average rating of “Moderate Buy” and an average price target of $279.17.

View Our Latest Analysis on Becton, Dickinson and Company

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $244.04 on Tuesday. Becton, Dickinson and Company has a 1-year low of $229.85 and a 1-year high of $287.32. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.08 and a quick ratio of 0.64. The business’s fifty day moving average price is $239.68 and its two-hundred day moving average price is $244.66. The firm has a market capitalization of $70.50 billion, a PE ratio of 57.83, a P/E/G ratio of 2.04 and a beta of 0.43.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last issued its earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share for the quarter, topping the consensus estimate of $2.39 by $0.29. Becton, Dickinson and Company had a return on equity of 13.57% and a net margin of 6.44%. The firm had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.73 billion. During the same period last year, the company earned $2.98 earnings per share. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. On average, research analysts expect that Becton, Dickinson and Company will post 12.94 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, March 29th. Stockholders of record on Friday, March 8th were paid a $0.95 dividend. The ex-dividend date of this dividend was Thursday, March 7th. This represents a $3.80 annualized dividend and a dividend yield of 1.56%. Becton, Dickinson and Company’s payout ratio is 90.05%.

Becton, Dickinson and Company Company Profile

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Featured Stories

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXFree Report).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.